Ensuring consistent diagnostic quality remains critical. In this video, Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discussed findings from the PRIME trial, a multicenter international ...
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...
BioTraceIO360 received FDA 510(k) clearance for kidney ablation, expanding its previous liver tumor ablation indication. The platform standardizes minimally invasive care, enhancing treatment planning ...
Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care. In discussing the links between diet and prostate cancer, Stephen J. Freedland, MD, a professor of ...
FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years and older. Recommended dosages are 395 mg/4800 units every 3 weeks or 790 mg/9600 units ...
Rhonda Stamey, APRN, is a key member of the Advanced Therapy Center Medical Team at First Urology, where she plays an active role in advancing the treatment of prostate cancer. She provides expert ...
FloStent enabled catheter-free voiding in men with BPH-related urinary retention, showing potential as an interim solution before TURP. At three months, 72.7% of patients remained catheter-free, with ...
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer ...
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer ...
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer ...
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer ...
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback